DIA
Drug Information Association Logo

DIA Marketing of Pharmaceuticals 2012 PRogram Focuses on the Latest Do's and Don'ts of Advertising and Marketing

Horsham, PA, USA — Jan 23, 2012

DIA will convene regulatory, legal, and communications professionals to explore the latest “rules of the road” during Marketing of Pharmaceuticals 2012, February 15 – 17, 2012 in Washington, DC.

The three-day program, geared towards the needs of your entire promotional team, will provide you with:

  • A better understanding of how the regulatory and legal environment has evolved and affects the marketing and promotion of pharmaceuticals, biologics, and medical devices
  • Practical, day-to-day guidance based from the latest FDA enforcement actions, as well as federal and state civil and criminal actions and settlements
  • Insight into FDA guidance documents and policies currently in development or being considered
  • Latest enforcement activities by the centers within FDA that regulate medical marketing: drugs (CDER), biological products (CBER), and medical devices (CDRH)
  • What’s new in Medical Policy Initiatives
  • Information about Substantial Evidence and other Standards

As evidenced by the FDA’s recent Social Media Marketing Draft Guidance, the regulatory dos and don’ts of medical product marketing have been big question marks for companies. Hear what regulatory experts have to say about the implications of this draft guidance. Featured FDA speakers include:

  • Jean-Ah Kang, PharmD, CDER
  • Thomas W. Abrams, MBA, RPh, CDER
  • Terri T. Garvin, CDRH
  • Deborah Wolf, CDRH

“It’s not getting any easier to understand or be in compliance with all the various regulatory and legal requirements that apply to Rx and OTC drug and device promotional materials,” say Program Committee Member Wayne L. Pines, President, Regulatory Services and Healthcare, APCO Worldwide, Inc. “Marketing Pharmaceuticals 2012 will provide insight into how to avoid the penalties for non-compliance.”

 

 

###

ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.